Litcius/Paper detail

Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia

Jenna Rossoff, Christina Baggott, Snehit Prabhu, Holly Pacenta, Christine L. Phillips, Heather E. Stefanski, Julie-An Talano, Amy Moskop, Steven Margossian, Michael R. Verneris, Gary Douglas Myers, Nicole Karras, Patrick A. Brown, Muna Qayed, Michelle L. Hermiston, Prakash Satwani, Christa Krupski, Amy K. Keating, Rachel Wilcox, Cara A. Rabik, Vanessa A. Fabrizio, Michael Kunicki, Vasant Chinnabhandar, A. Yasemin Goksenin, Kevin J. Curran, Crystal L. Mackall, Theodore W. Laetsch, Liora M. Schultz

2021Blood13 citationsDOIOpen Access PDF

Topics & Concepts

MedicineBlinatumomabLymphoblastic LeukemiaAcute lymphocytic leukemiaLeukemiaIntensive care medicineImmunologyCAR-T cell therapy researchVirus-based gene therapy researchImmune Cell Function and Interaction
Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia | Litcius